Your browser doesn't support javascript.
loading
Treatment of chronic cough: P2X3 receptor antagonists and beyond.
Sykes, Dominic L; Zhang, Mengru; Morice, Alyn H.
Afiliación
  • Sykes DL; Respiratory Research Group, Hull York Medical School, Hull, United Kingdom.
  • Zhang M; Respiratory Research Group, Hull York Medical School, Hull, United Kingdom.
  • Morice AH; Respiratory Research Group, Hull York Medical School, Hull, United Kingdom. Electronic address: a.h.morice@hull.ac.uk.
Pharmacol Ther ; 237: 108166, 2022 09.
Article en En | MEDLINE | ID: mdl-35263649
ABSTRACT
For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiological mechanisms of CC, primarily the recognition of neuronal dysregulation in its aetiology, there appears to be a new hope for such patients. In this review we discuss the multitude of proposed pharmacological targets in CC, including the promising results produced by the antagonism of P2X3 receptors. We also assess the evidence of other peripherally acting pharmacolgical agents still in development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tos / Antagonistas del Receptor Purinérgico P2X Límite: Humans Idioma: En Revista: Pharmacol Ther Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tos / Antagonistas del Receptor Purinérgico P2X Límite: Humans Idioma: En Revista: Pharmacol Ther Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido